Stem definition | Drug id | CAS RN |
---|---|---|
692 | 2030-63-9 |
Dose | Unit | Route |
---|---|---|
0.10 | g | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.00 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.20 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 7.03 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 57 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 15, 1986 | FDA | NOVARTIS |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Electrocardiogram QT prolonged | 399.88 | 27.85 | 153 | 4057 | 51733 | 50549181 |
Drug resistance | 117.71 | 27.85 | 48 | 4162 | 18941 | 50581973 |
Neuropathy peripheral | 98.74 | 27.85 | 74 | 4136 | 96683 | 50504231 |
Anaemia | 85.83 | 27.85 | 105 | 4105 | 252351 | 50348563 |
Hepatotoxicity | 83.10 | 27.85 | 42 | 4168 | 27184 | 50573730 |
Vomiting | 78.31 | 27.85 | 138 | 4072 | 460620 | 50140294 |
Optic neuropathy | 74.36 | 27.85 | 19 | 4191 | 1675 | 50599239 |
Off label use | 74.11 | 27.85 | 137 | 4073 | 474289 | 50126625 |
Type 2 lepra reaction | 71.43 | 27.85 | 10 | 4200 | 25 | 50600889 |
Intentional product use issue | 59.42 | 27.85 | 50 | 4160 | 76868 | 50524046 |
Skin hyperpigmentation | 56.87 | 27.85 | 20 | 4190 | 5256 | 50595658 |
Polyneuropathy | 53.13 | 27.85 | 24 | 4186 | 12107 | 50588807 |
Respiratory failure | 50.20 | 27.85 | 49 | 4161 | 91132 | 50509782 |
Drug reaction with eosinophilia and systemic symptoms | 48.67 | 27.85 | 30 | 4180 | 28394 | 50572520 |
Skin discolouration | 47.20 | 27.85 | 31 | 4179 | 32726 | 50568188 |
Myelosuppression | 44.60 | 27.85 | 22 | 4188 | 13495 | 50587419 |
Product use in unapproved indication | 43.83 | 27.85 | 51 | 4159 | 115768 | 50485146 |
Aspartate aminotransferase increased | 39.37 | 27.85 | 40 | 4170 | 77958 | 50522956 |
Drug-induced liver injury | 34.29 | 27.85 | 24 | 4186 | 28071 | 50572843 |
Haemoptysis | 33.93 | 27.85 | 23 | 4187 | 25550 | 50575364 |
Meningitis tuberculous | 33.53 | 27.85 | 8 | 4202 | 531 | 50600383 |
Herbal toxicity | 32.11 | 27.85 | 5 | 4205 | 31 | 50600883 |
Alanine aminotransferase increased | 30.25 | 27.85 | 37 | 4173 | 88322 | 50512592 |
Mycobacterial infection | 29.09 | 27.85 | 9 | 4201 | 1587 | 50599327 |
Pyelonephritis chronic | 28.70 | 27.85 | 6 | 4204 | 217 | 50600697 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Electrocardiogram QT prolonged | 535.82 | 25.55 | 206 | 4627 | 35931 | 29533763 |
Type 2 lepra reaction | 248.14 | 25.55 | 40 | 4793 | 143 | 29569551 |
Hepatotoxicity | 171.91 | 25.55 | 75 | 4758 | 17792 | 29551902 |
Intentional product use issue | 127.97 | 25.55 | 82 | 4751 | 42416 | 29527278 |
Neuropathy peripheral | 119.17 | 25.55 | 96 | 4737 | 70931 | 29498763 |
Off label use | 103.27 | 25.55 | 179 | 4654 | 300621 | 29269073 |
Deafness | 64.75 | 25.55 | 32 | 4801 | 10023 | 29559671 |
Skin hyperpigmentation | 63.22 | 25.55 | 22 | 4811 | 2842 | 29566852 |
Incorrect product administration duration | 62.95 | 25.55 | 24 | 4809 | 4017 | 29565677 |
Anaemia | 58.91 | 25.55 | 112 | 4721 | 200839 | 29368855 |
Ototoxicity | 58.86 | 25.55 | 18 | 4815 | 1547 | 29568147 |
Type 1 lepra reaction | 56.06 | 25.55 | 9 | 4824 | 31 | 29569663 |
Vomiting | 48.77 | 25.55 | 107 | 4726 | 212153 | 29357541 |
Product use in unapproved indication | 45.32 | 25.55 | 63 | 4770 | 86812 | 29482882 |
Optic neuropathy | 40.90 | 25.55 | 14 | 4819 | 1721 | 29567973 |
Tuberculosis | 40.75 | 25.55 | 21 | 4812 | 7175 | 29562519 |
Nausea | 40.57 | 25.55 | 121 | 4712 | 289134 | 29280560 |
Drug resistance | 40.04 | 25.55 | 31 | 4802 | 21509 | 29548185 |
Tinnitus | 39.31 | 25.55 | 27 | 4806 | 15587 | 29554107 |
Acoustic neuroma | 38.18 | 25.55 | 8 | 4825 | 145 | 29569549 |
HIV infection | 37.77 | 25.55 | 12 | 4821 | 1169 | 29568525 |
Drug-induced liver injury | 37.73 | 25.55 | 30 | 4803 | 21625 | 29548069 |
Hypertriglyceridaemia | 37.17 | 25.55 | 20 | 4813 | 7455 | 29562239 |
Aspartate aminotransferase increased | 36.78 | 25.55 | 47 | 4786 | 59678 | 29510016 |
Polyneuropathy | 35.37 | 25.55 | 23 | 4810 | 12129 | 29557565 |
Myelosuppression | 35.24 | 25.55 | 23 | 4810 | 12204 | 29557490 |
Deafness neurosensory | 32.02 | 25.55 | 13 | 4820 | 2565 | 29567129 |
Blood sodium decreased | 31.31 | 25.55 | 23 | 4810 | 14744 | 29554950 |
Toxic optic neuropathy | 29.91 | 25.55 | 9 | 4824 | 732 | 29568962 |
Optic neuritis | 29.67 | 25.55 | 13 | 4820 | 3096 | 29566598 |
Iridocyclitis | 27.74 | 25.55 | 10 | 4823 | 1430 | 29568264 |
Vestibular disorder | 26.79 | 25.55 | 9 | 4824 | 1045 | 29568649 |
Oral candidiasis | 25.71 | 25.55 | 18 | 4815 | 10704 | 29558990 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Electrocardiogram QT prolonged | 863.00 | 22.66 | 347 | 8716 | 79101 | 64410568 |
Type 2 lepra reaction | 314.49 | 22.66 | 49 | 9014 | 161 | 64489508 |
Neuropathy peripheral | 241.85 | 22.66 | 169 | 8894 | 117356 | 64372313 |
Hepatotoxicity | 235.49 | 22.66 | 114 | 8949 | 39848 | 64449821 |
Intentional product use issue | 175.00 | 22.66 | 128 | 8935 | 95236 | 64394433 |
Off label use | 167.54 | 22.66 | 309 | 8754 | 632497 | 63857172 |
Drug resistance | 145.35 | 22.66 | 79 | 8984 | 35023 | 64454646 |
Anaemia | 132.88 | 22.66 | 210 | 8853 | 378470 | 64111199 |
Optic neuropathy | 111.25 | 22.66 | 33 | 9030 | 2978 | 64486691 |
Vomiting | 105.83 | 22.66 | 236 | 8827 | 550881 | 63938788 |
Skin hyperpigmentation | 104.37 | 22.66 | 38 | 9025 | 6513 | 64483156 |
Deafness | 89.21 | 22.66 | 46 | 9017 | 18313 | 64471356 |
Polyneuropathy | 88.55 | 22.66 | 47 | 9016 | 19847 | 64469822 |
Incorrect product administration duration | 83.08 | 22.66 | 36 | 9027 | 9722 | 64479947 |
Type 1 lepra reaction | 77.57 | 22.66 | 12 | 9051 | 37 | 64489632 |
Product use in unapproved indication | 76.03 | 22.66 | 108 | 8955 | 176510 | 64313159 |
Myelosuppression | 75.36 | 22.66 | 45 | 9018 | 23785 | 64465884 |
Ototoxicity | 71.62 | 22.66 | 23 | 9040 | 2700 | 64486969 |
Aspartate aminotransferase increased | 68.12 | 22.66 | 84 | 8979 | 119704 | 64369965 |
Skin discolouration | 63.80 | 22.66 | 47 | 9016 | 35208 | 64454461 |
Drug-induced liver injury | 61.41 | 22.66 | 52 | 9011 | 47591 | 64442078 |
Tinnitus | 60.63 | 22.66 | 45 | 9018 | 34088 | 64455581 |
Drug reaction with eosinophilia and systemic symptoms | 57.54 | 22.66 | 53 | 9010 | 54164 | 64435505 |
HIV infection | 46.24 | 22.66 | 13 | 9050 | 969 | 64488700 |
Respiratory failure | 45.06 | 22.66 | 81 | 8982 | 161102 | 64328567 |
Meningitis tuberculous | 44.65 | 22.66 | 13 | 9050 | 1098 | 64488571 |
Alanine aminotransferase increased | 44.25 | 22.66 | 74 | 8989 | 138957 | 64350712 |
Nausea | 42.75 | 22.66 | 220 | 8843 | 785580 | 63704089 |
Tuberculosis | 42.20 | 22.66 | 25 | 9038 | 13013 | 64476656 |
Toxic optic neuropathy | 42.16 | 22.66 | 12 | 9051 | 935 | 64488734 |
Psychotic disorder | 41.01 | 22.66 | 36 | 9027 | 34542 | 64455127 |
Pulmonary tuberculosis | 40.60 | 22.66 | 20 | 9043 | 7224 | 64482445 |
Hypokalaemia | 40.29 | 22.66 | 66 | 8997 | 121837 | 64367832 |
Optic neuritis | 38.45 | 22.66 | 20 | 9043 | 8096 | 64481573 |
Hypertriglyceridaemia | 37.61 | 22.66 | 22 | 9041 | 11183 | 64478486 |
Haemoptysis | 37.29 | 22.66 | 40 | 9023 | 49008 | 64440661 |
Acoustic neuroma | 35.89 | 22.66 | 8 | 9055 | 229 | 64489440 |
Pain | 35.13 | 22.66 | 17 | 9046 | 553494 | 63936175 |
Pneumothorax | 34.37 | 22.66 | 28 | 9035 | 24270 | 64465399 |
Deafness neurosensory | 33.95 | 22.66 | 17 | 9046 | 6357 | 64483312 |
Fall | 32.85 | 22.66 | 9 | 9054 | 416817 | 64072852 |
Treatment noncompliance | 32.25 | 22.66 | 35 | 9028 | 43447 | 64446222 |
Hypoacusis | 30.81 | 22.66 | 27 | 9036 | 25840 | 64463829 |
Bicytopenia | 29.64 | 22.66 | 13 | 9050 | 3609 | 64486060 |
Decreased appetite | 27.13 | 22.66 | 94 | 8969 | 281195 | 64208474 |
Infective pulmonary exacerbation of cystic fibrosis | 26.60 | 22.66 | 18 | 9045 | 11778 | 64477891 |
Transaminases increased | 26.48 | 22.66 | 32 | 9031 | 44562 | 64445107 |
Blood sodium decreased | 25.93 | 22.66 | 26 | 9037 | 29456 | 64460213 |
Cardiopulmonary failure | 25.82 | 22.66 | 14 | 9049 | 6156 | 64483513 |
Mycobacterial infection | 25.35 | 22.66 | 11 | 9052 | 2977 | 64486692 |
Malnutrition | 24.88 | 22.66 | 21 | 9042 | 19104 | 64470565 |
Vestibular disorder | 24.68 | 22.66 | 10 | 9053 | 2283 | 64487386 |
Pyelonephritis chronic | 24.47 | 22.66 | 6 | 9057 | 262 | 64489407 |
Herbal toxicity | 23.05 | 22.66 | 4 | 9059 | 29 | 64489640 |
Facial paralysis | 22.99 | 22.66 | 20 | 9043 | 18946 | 64470723 |
None
Source | Code | Description |
---|---|---|
ATC | J04BA01 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIMYCOBACTERIALS DRUGS FOR TREATMENT OF LEPRA Drugs for treatment of lepra |
FDA EPC | N0000175483 | Antimycobacterial |
CHEBI has role | CHEBI:35475 | non-steroidal anti-inflammatory agent |
CHEBI has role | CHEBI:35816 | leprostatic drugs |
CHEBI has role | CHEBI:37958 | dyes |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
MeSH PA | D000893 | Anti-Inflammatory Agents |
MeSH PA | D007917 | Leprostatic Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Pyoderma gangrenosum | indication | 74578003 | DOID:8553 |
Leprosy | indication | 81004002 | DOID:1024 |
Erythema nodosum leprosum | indication | 240411003 | |
Multibacillary leprosy | indication | 416257001 | |
Dapsone resistant leprosy | indication | 416597004 | |
Mycobacteriosis | off-label use | 88415009 | |
Nausea and vomiting | contraindication | 16932000 | |
Splenic infarction | contraindication | 22996003 | DOID:2533 |
Disorder of digestive system | contraindication | 53619000 | DOID:77 |
Diarrhea | contraindication | 62315008 | |
Gastrointestinal hemorrhage | contraindication | 74474003 | |
Gastrointestinal obstruction | contraindication | 126765001 | |
Disease of liver | contraindication | 235856003 | DOID:409 |
Breastfeeding (mother) | contraindication | 413712001 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 8.81 | Basic |
pKa2 | 5.53 | Basic |
pKa3 | 2.07 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Uncharacterized oxidoreductase CzcO-like | Enzyme | WOMBAT-PK | |||||||
Cruzipain | Enzyme | IC50 | 5.22 | CHEMBL |
ID | Source |
---|---|
4019504 | VUID |
N0000147624 | NUI |
D00278 | KEGG_DRUG |
203021 | RXNORM |
4019504 | VANDF |
C0008996 | UMLSCUI |
CHEBI:3749 | CHEBI |
CHEMBL1292 | ChEMBL_ID |
D002991 | MESH_DESCRIPTOR_UI |
DB00845 | DRUGBANK_ID |
9184 | IUPHAR_LIGAND_ID |
2248 | INN_ID |
D959AE5USF | UNII |
2794 | PUBCHEM_CID |
1685 | MMSL |
4473 | MMSL |
d01121 | MMSL |
003007 | NDDF |
387410004 | SNOMEDCT_US |
72924009 | SNOMEDCT_US |
None